On November 5, 2025 Verismo Therapeutics, a clinical-stage CAR T company developing a novel KIR-CAR platform technology, reported its participation at the upcoming Society of Immunotherapy in Cancer (SITC) (Free SITC Whitepaper) 2025 Annual Meeting and American Society of Hematology (ASH) (Free ASH Whitepaper) 2025 Annual Meeting. The company will present new preclinical and translational data supporting the advancement of its clinical pipelines, SynKIR-110 and SynKIR-310.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company’s presentations will include:
SITC 2025 Annual Meeting
November 7-9, 2025 – Gaylord National Resort and Convention Center, National Harbor, Maryland
Verismo’s team will deliver three presentations:
An oral and a poster presentation on new preclinical in vitro and in vivo results to investigate functionality, safety and tumor killing of SynKIR-110, Verismo’s lead pipeline targeting mesothelin
Location: Gaylord National Resort & Convention Center, National Harbor 2-3
Abstract Number: 298
Abstract Title: A Novel NK-cell based Split-Signaling Killer Immunoglobulin Receptor (KIR)-Based CAR T Targeting Mesothelin, SynKIR-110, Shows Increased Safety Profile and Increased Efficacy in vitro and in vivo
Presenting Author: Nora Yucel, PhD
Oral Session Title: Oral Abstract Session 2
Oral Session Date and Time: Friday, Nov. 7, 2025: 4:45PM – 5:00PM
Poster Session Title: Exhibits and Poster Viewing
Poster Session Date and Time: Saturday, Nov 8, 2025: 12:15 – 1:45 PM, 5:10 – 6:35 PM
A poster presentation on immunohistochemistry (IHC) detection of mesothelin to support further development of CAR T cell therapy in cholangiocarcinoma.
Location: Prince George ABC Exhibit Halls Gaylord National Resort and Convention Center
Abstract Number: 1238
Abstract Title: Histopathologic analysis of mesothelin expression in cholangiocarcinoma supports inclusion in biomarker-targeted clinical trials
Presenting Author: Adina Vultur, PhD
Session Title: Exhibits & Poster Viewing
Session Date and Time: Saturday, Nov. 8, 2025: 12:15 – 1:45 PM, 5:10 – 6:35 PM
A poster presentation highlighting key considerations for ensuring the timely release of patient materials to support clinical development.
Location: Prince George ABC Exhibit Halls Gaylord National Resort and Convention Center
Abstract Number: 591
Abstract Title: The Need for Speed Without Compromising Quality in Manufacturing Autologous Cell Therapy Products
Presenting Author: Jacqueline Stief
Session Title: Exhibits and Poster Viewing
Session Date: Friday, Nov. 7, 2025: 12:1 5- 1:45 PM, 5:35 – 7 PM
ASH 2025 Annual Meeting
December 6-9, 2025 – Orange County Convention Center, Orlando, Florida
Verismo’s team will deliver a poster presentation highlighting the potent antitumor activity of SynKIR-310, a novel CD19-targeted KIR-CAR T cell therapy, in a preclinical mouse model.
Location: Orange County Convention Center – West Halls B3-B4
Abstract Number: 4103
Abstract Title: SynKIR-310 split-signaling based KIR-CAR T cell therapy achieves faster and deeper anti-B cell tumor efficacy with reduced cytokine levels
Presenting Author: Megan Blair, PhD
Session Title: 702. CAR-T Cell Therapies: Basic and Translational: Poster II
Session Date and Time: Sunday, Dec. 7, 2025: 6:00 PM – 8:00 PM
(Press release, Verismo Therapeutics, NOV 5, 2025, View Source [SID1234659489])